Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

• DOI: 10.1371/journal.pone.0265235
• Publication Date: 2022-03-10T18:51:17Z
• Authors: Shun Kaneko; Masayuki Kurosaki; Kaoru Tsuchiya; Yutaka Yasui; Yuka Hayakawa; Kento Inada; Yuki Tanaka; Shun Ishido; Sakura Kirino; Koji Yamashita; Tsubasa Nobusawa; Hiroaki Matsumoto; Tatsuya Kakegawa; Mayu Higuchi; Kenta Takaura; Shohei Tanaka; Chiaki Maeyashiki; Nobuharu Tamaki; Yuka Takahashi; Hiroyuki Nakanishi; Namiki Izumi
• Keywords: Carcinoma, Hepatocellular; Vitamin K; Science; Q; Liver Neoplasms; R; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Biomarkers, Tumor; Medicine; Humans; Prothrombin; Prospective Studies; alpha-Fetoproteins; Protein Precursors; Multiple Myeloma; Biomarkers; Research Article

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies advanced HCC has been remarkable, role PIVKA-II is unclear. This prospective study aimed to verify Elecsys compared with Lumipulse in cohort undergoing therapy.A total 62 patients who were treated atezolizumab bevacizumab (ATZ+BEV) molecular targeted agents (MTAs) prospectively enrolled at Musashino Red Cross Hospital from January 2020 December 2020. A 208 serum samples 52 tested using assays. Furthermore, relationship progression-free survival (PFS) investigated 48 (24 ATZ+BEV 24 MTAs) whose levels >40 mAU/mL.In test accuracy analysis, assay correlation coefficient (R) 0.92 that (ATZ+BEV, 0.95; MTAs, 0.91). In PFS number received MTAs first- late-line therapy 9 13, 15 11, respectively. The response defined had reduction level on first month treatment evaluation. significantly longer than nonresponse (5.8 months vs 3.8 months, p = 0.0205).The not only useful but also stratifying HCC.